Datri Blood Stem Cell Donors Registry Profile
Key Indicators
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 65.18%
(FY 2023)
- Profit -2816.69%
(FY 2023)
- Ebitda -6227.99%
(FY 2023)
- Net Worth -4.66%
(FY 2023)
- Total Assets -31.10%
(FY 2023)
About Datri Blood Stem Cell Donors Registry
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.00 and a paid-up capital of Rs 0.00, as per Ministry of Corporate Affairs (MCA) records.
Soo Lee, Nezih Cereb, and Nagarajan serve as directors at the Company.
- CIN/LLPIN
U85190TN2009NPL070883
- Company No.
070883
- Company Classification
Private Not For Profit Company
- Incorporation Date
03 Mar 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Datri Blood Stem Cell Donors Registry?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagarajan  | Director | 30-Nov-2019 | Current |
Soo Lee  | Director | 03-Mar-2009 | Current |
| Nezih Cereb | Director | 03-Mar-2009 | Current |
Financial Performance and Corporate Structure Insights of Datri Blood Stem Cell Donors Registry.
Datri Blood Stem Cell Donors Registry, for the financial year ended 2023, experienced significant growth in revenue, with a 65.18% increase. The company also saw a substantial fall in profitability, with a 2816.69% decrease in profit. The company's net worth dipped by a decrease of 4.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Datri Blood Stem Cell Donors Registry?
Unlock access to Datri Blood Stem Cell Donors Registry's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Histogenetics (India) Private LimitedActive 18 years 1 daySoo Lee, Nezih Cereb and 1 more are mutual person
_PRIVATE_LIMITED.webp)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Datri Blood Stem Cell Donors Registry?
Datri Blood Stem Cell Donors Registry has a workforce of 67 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Datri Blood Stem Cell Donors Registry, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Datri Blood Stem Cell Donors Registry's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
